Key result
Graphene-derived multiplexed biosensors offer significant potential for fast, high-precision detection of cardiac biomarkers to enhance point-of-care cardiovascular health assessments.
Why the study?
The escalating global prevalence of cardiovascular diseases requires low-cost monitoring technology for immediate intervention and diagnosis, but research and development are needed to fully harness graphene-derived multiplexed biosensors in clinical environments.
Graphene-derived multiplexed biosensors show substantial potential for rapid, low-cost point-of-care detection of cardiac biomarkers, though further research is needed for clinical translation.
Answers are grounded in this paper and cite their sources.
Graphene multiplexed biosensors should not yet change cardiac diagnostic practice; leaves open their clinical translation for point-of-care use.
The escalating prevalence of cardiovascular diseases globally call for a low-cost monitoring technology for an immediate intervene and diagnoses. Advance multiplexed biosensors reinforced by graphene derivatives marks a significant progression in the field of cardiovascular health assessments. The graphene derived biosensors are designed specifically for fast detection of cardiac biomarkers with high precision to evaluate cardiovascular health. The graphene biocompatibility and fast signal transduction electronic properties provide an ideal foundation for the multiplexed technology. Despite the substantial potential of this multiplexed technologies, there remains a pressing need for further research and development to fully harness their capabilities in clinical environments. This study underscores the critical role of these biosensors in point of care applications and reviews the current landscape of research, highlighting significant progress made in graphene-based transduction and the recent trends in graphene production which give impact on biosensors performance. Key components are discussed include the assessment of vital cardiac biomarkers and the evolution of multiplex biosensing strategies that utilizes graphene nanomaterials. In summary, this review provides a comprehensive overview of the latest advancements in multi-analyte detection for cardiac healthcare. It outlines the key challenges encountered while proposing potential strategies to improve the effectiveness of multiplex biosensing platforms, thereby supporting the advancement of cardiac diagnostics. The potential of multiplexed biosensing technology leads to enhance diagnostic capabilities while reducing healthcare costs represents a significant advancement in cardiovascular healthcare, particularly for point-of-care applications.
No takes yet. Share an insight, caveat, or question.
Suhaimi et al. (2025) conducted a review in Cardiovascular diseases. Graphene derived multiplexed biosensors was evaluated. Graphene-derived multiplexed biosensors offer significant potential for fast, high-precision detection of cardiac biomarkers to enhance point-of-care cardiovascular health assessments.
Synapse has enriched 10 related papers. Consider them for comparative context: